PKTX Stock Overview
A research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
ProtoKinetix, Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.01 |
52 Week High | US$0.03 |
52 Week Low | US$0.008 |
Beta | 0.17 |
11 Month Change | -27.27% |
3 Month Change | -49.49% |
1 Year Change | -58.90% |
33 Year Change | -93.33% |
5 Year Change | -96.15% |
Change since IPO | 150.00% |
Recent News & Updates
Recent updates
Shareholder Returns
PKTX | US Biotechs | US Market | |
---|---|---|---|
7D | -6.5% | -0.7% | 0.04% |
1Y | -58.9% | 10.0% | 20.7% |
Return vs Industry: PKTX underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: PKTX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
PKTX volatility | |
---|---|
PKTX Average Weekly Movement | 20.6% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PKTX's share price has been volatile over the past 3 months.
Volatility Over Time: PKTX's weekly volatility has decreased from 26% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Clarence Smith | www.protokinetix.com |
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia.
ProtoKinetix, Incorporated Fundamentals Summary
PKTX fundamental statistics | |
---|---|
Market cap | US$3.53m |
Earnings (TTM) | -US$400.47k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.8x
P/E RatioIs PKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PKTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$400.47k |
Earnings | -US$400.47k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0011 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PKTX perform over the long term?
See historical performance and comparison